Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry

초록

IntroductionData concerning the clinical impact of combination therapy with -blockers (BBs)+angiotensin-converting enzyme inhibitors (ACEIs) compared with BBs+angiotensin-receptor blockers (ARBs) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are limited.ObjectiveWe compared the clinical outcomes at 2years between these two combination therapies.MethodsWe enrolled 23,978 patients with AMI who underwent successful PCI with DES between January 2005 and June 2015 from the Korea AMI Registry (KAMIR) and divided them into the two groups: BB+ACEI (n=17,310) and BB+ARB (n=6668). The primary endpoint was major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (re-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR. The secondary endpoints were the cumulative incidences of individual components of MACE and target vessel failure (TVF), a composite of death related to the target vessel, re-MI, or clinically driven TVR.ResultsThe relative risk of MACE was higher in the BB+ARB group than in the BB+ACEI group after propensity score-matched (PSM) analysis (hazard ratio [HR] 1.204; 95% confidence interval [CI] 1.057-1.370; p=0.005). The relative risks of all-cause death (HR 1.435 [95% CI 1.117-1.845]; p=0.005), cardiac death (HR 1.733 [95% CI 1.253-2.396]; p=0.001), TVR (HR 1.437 [95% CI 1.157-1.784]; p=0.001), and TVF (HR 1.231 [95% CI 1.065-1.424]; p=0.005) were also higher in the BB+ARB group after PSM.ConclusionsThe BB+ACEI group demonstrated reduced cumulative incidences of MACE, all-cause death, cardiac death, TVR, and TVF compared with the BB+ARB group in patients with AMI who underwent successful PCI with DES during a 2-year follow-up period.

키워드